BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31484798)

  • 1. Can a subgroup at high risk for LRR be identified from T1-2 breast cancer with negative lymph nodes after mastectomy? A meta-analysis.
    Peng G; Zhou Z; Jiang M; Yang F
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31484798
    [No Abstract]   [Full Text] [Related]  

  • 2. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
    Mamtani A; Patil S; Stempel MM; Morrow M
    Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
    Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes.
    Moo TA; McMillan R; Lee M; Stempel M; Ho A; Patil S; El-Tamer M
    Ann Surg Oncol; 2014 May; 21(5):1569-74. PubMed ID: 24488216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.
    Moo TA; McMillan R; Lee M; Stempel M; Patil S; Ho A; El-Tamer M
    Ann Surg Oncol; 2013 Oct; 20(10):3169-74. PubMed ID: 23975289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.
    Muhsen S; Moo TA; Patil S; Stempel M; Powell S; Morrow M; El-Tamer M
    Ann Surg Oncol; 2018 Jul; 25(7):1912-1920. PubMed ID: 29564588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
    Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status.
    Yang PS; Chen CM; Liu MC; Jian JM; Horng CF; Liu MJ; Yu BL; Lee MY; Chi CW
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):516-22. PubMed ID: 19577858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of postmastectomy radiation therapy on high-risk patients with T1-2N0 breast cancer.
    Luo C; Zhong X; Fan Y; Wang C; Wang Y; Luo T
    Breast; 2021 Dec; 60():1-5. PubMed ID: 34455226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
    Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
    Truong PT; Jones SO; Kader HA; Wai ES; Speers CH; Alexander AS; Olivotto IA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):357-64. PubMed ID: 18676091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumor and 1-3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases.
    Shen H; Zhao L; Wang L; Liu X; Liu X; Liu J; Niu F; Lv S; Niu Y
    Tumour Biol; 2016 May; 37(5):6465-75. PubMed ID: 26631044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.
    Abi-Raad R; Boutrus R; Wang R; Niemierko A; Macdonald S; Smith B; Taghian AG
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e151-7. PubMed ID: 21420245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
    Zhao JM; An Q; Sun CN; Li YB; Qin ZL; Guo H; Zeng X; Zhang YT; Wei LL; Han N; Sun SC; Zhang N
    Breast Cancer; 2021 Mar; 28(2):298-306. PubMed ID: 32940902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23).
    Park HJ; Shin KH; Kim JH; Ahn SD; Kim JY; Park W; Kim YB; Kim YJ; Kim JH; Kim K; Park KR; Shin HS; Jeong BK; Lee SY; Kim S
    Cancer Res Treat; 2017 Jul; 49(3):739-747. PubMed ID: 27764904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy?
    Jwa E; Shin KH; Lim HW; Jung SY; Lee S; Kang HS; Lee E; Park YH
    PLoS One; 2015; 10(12):e0145463. PubMed ID: 26691445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
    Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
    Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.